Literature DB >> 19605641

Reduction of the rate of protein translation in patients with myotonic dystrophy 2.

Claudia Huichalaf1, Benedikt Schoser, Christiane Schneider-Gold, Bingwen Jin, Partha Sarkar, Lubov Timchenko.   

Abstract

Myotonic dystrophy 2 (DM2) is an autosomal dominant, multisystem disease, which primarily affects skeletal muscle. DM2 is caused by CCTGn expansion in the intron 1 of the ZNF9 gene. Expression of the mutant CCUGn RNA changes RNA processing in patients with DM2; however, the role of ZNF9 protein in DM2 pathology has been not elucidated. ZNF9 has been shown to regulate cap-dependent and cap-independent translation. We have examined a possible role of ZNF9 in the regulation of translation in DM2 patients. We found that ZNF9 interacts with the 5' UTRs of terminal oligopyrimidine (TOP) tract mRNAs encoding human ribosomal protein, RPS17, poly(A)-binding protein 1 (PABP1), and the elongation factors, eEF1A and eEF2. The binding activity of ZNF9 toward these TOP-containing 5' UTRs is reduced in DM2 muscle. Consistent with the reduction of this activity, the levels of RPS17, PABP, eEF1A, and eEF2 proteins are also diminished in DM2 muscle. The reduction of ZNF9 RNA-binding activity in DM2 correlates with a decrease of ZNF9 protein levels in cytoplasm of DM2 muscle cells. We found that the reduction of ZNF9 is caused by expression of the mutant CCUG repeats. This decrease of proteins of translational apparatus in DM2 correlates with a reduction of a rate of protein synthesis in myoblasts from DM2 patients. We found that the ectopic expression of ZNF9 in DM2 myoblasts corrects rate of protein synthesis, suggesting that the alterations in CCUG-ZNF9-TOP mRNAs pathway are responsible for the reduction of the rate of protein translation in DM2 muscle cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19605641      PMCID: PMC3610333          DOI: 10.1523/JNEUROSCI.1983-09.2009

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  27 in total

Review 1.  Synthesis of the translational apparatus is regulated at the translational level.

Authors:  O Meyuhas
Journal:  Eur J Biochem       Date:  2000-11

2.  Molecular basis for impaired muscle differentiation in myotonic dystrophy.

Authors:  N A Timchenko; P Iakova; Z J Cai; J R Smith; L T Timchenko
Journal:  Mol Cell Biol       Date:  2001-10       Impact factor: 4.272

3.  Identification of a zinc finger protein that binds to the sterol regulatory element.

Authors:  T B Rajavashisth; A K Taylor; A Andalibi; K L Svenson; A J Lusis
Journal:  Science       Date:  1989-08-11       Impact factor: 47.728

4.  Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum.

Authors:  J W Day; K Ricker; J F Jacobsen; L J Rasmussen; K A Dick; W Kress; C Schneider; M C Koch; G J Beilman; A R Harrison; J C Dalton; L P W Ranum
Journal:  Neurology       Date:  2003-02-25       Impact factor: 9.910

5.  Expression of RNA CCUG repeats dysregulates translation and degradation of proteins in myotonic dystrophy 2 patients.

Authors:  Elizabeth Salisbury; Benedikt Schoser; Christiane Schneider-Gold; Guo-Li Wang; Claudia Huichalaf; Bingwen Jin; Mario Sirito; Partha Sarkar; Ralf Krahe; Nikolai A Timchenko; Lubov T Timchenko
Journal:  Am J Pathol       Date:  2009-07-09       Impact factor: 4.307

6.  Insulin receptor splicing alteration in myotonic dystrophy type 2.

Authors:  R S Savkur; A V Philips; T A Cooper; J C Dalton; M L Moseley; L P W Ranum; J W Day
Journal:  Am J Hum Genet       Date:  2004-04-26       Impact factor: 11.025

7.  Overexpression of CUG triplet repeat-binding protein, CUGBP1, in mice inhibits myogenesis.

Authors:  Nikolai A Timchenko; Roma Patel; Polina Iakova; Zong-Jin Cai; Ling Quan; Lubov T Timchenko
Journal:  J Biol Chem       Date:  2004-01-13       Impact factor: 5.157

8.  Homozygosity for CCTG mutation in myotonic dystrophy type 2.

Authors:  Benedikt G H Schoser; Wolfram Kress; Maggie C Walter; Birgit Halliger-Keller; Hanns Lochmüller; Kenneth Ricker
Journal:  Brain       Date:  2004-07-01       Impact factor: 13.501

9.  Cloning of the essential myotonic dystrophy region and mapping of the putative defect.

Authors:  C Aslanidis; G Jansen; C Amemiya; G Shutler; M Mahadevan; C Tsilfidis; C Chen; J Alleman; N G Wormskamp; M Vooijs
Journal:  Nature       Date:  1992-02-06       Impact factor: 49.962

Review 10.  Myotonic dystrophy: RNA pathogenesis comes into focus.

Authors:  Laura P W Ranum; John W Day
Journal:  Am J Hum Genet       Date:  2004-04-02       Impact factor: 11.025

View more
  40 in total

1.  Stress puts TIA on TOP.

Authors:  Pavel Ivanov; Nancy Kedersha; Paul Anderson
Journal:  Genes Dev       Date:  2011-10-15       Impact factor: 11.361

2.  Thermal injury activates the eEF2K-dependent eEF2 pathway in pediatric patients.

Authors:  Juquan Song; Celeste C Finnerty; David N Herndon; Robert Kraft; Darren Boehning; Natasha C Brooks; Ronald G Tompkins; Marc G Jeschke
Journal:  JPEN J Parenter Enteral Nutr       Date:  2012-01-23       Impact factor: 4.016

3.  Reduction of Cellular Nucleic Acid Binding Protein Encoded by a Myotonic Dystrophy Type 2 Gene Causes Muscle Atrophy.

Authors:  Christina Wei; Lauren Stock; Christiane Schneider-Gold; Claudia Sommer; Nikolai A Timchenko; Lubov Timchenko
Journal:  Mol Cell Biol       Date:  2018-06-28       Impact factor: 4.272

4.  Mutant (CCTG)n expansion causes abnormal expression of zinc finger protein 9 (ZNF9) in myotonic dystrophy type 2.

Authors:  Olayinka Raheem; Shodimu-Emmanuel Olufemi; Linda L Bachinski; Anna Vihola; Mario Sirito; Jeanette Holmlund-Hampf; Hannu Haapasalo; Yi-Ping Li; Bjarne Udd; Ralf Krahe
Journal:  Am J Pathol       Date:  2010-10-22       Impact factor: 4.307

5.  RNA Foci, CUGBP1, and ZNF9 are the primary targets of the mutant CUG and CCUG repeats expanded in myotonic dystrophies type 1 and type 2.

Authors:  Karlie Jones; Bingwen Jin; Polina Iakova; Claudia Huichalaf; Partha Sarkar; Christiane Schneider-Gold; Benedikt Schoser; Giovanni Meola; Ann-Bin Shyu; Nikolai Timchenko; Lubov Timchenko
Journal:  Am J Pathol       Date:  2011-09-01       Impact factor: 4.307

Review 6.  Myotonic dystrophy type 2 and modifier genes: an update on clinical and pathomolecular aspects.

Authors:  Giovanni Meola; Rosanna Cardani
Journal:  Neurol Sci       Date:  2017-01-11       Impact factor: 3.307

Review 7.  Myotonic dystrophy.

Authors:  Charles A Thornton
Journal:  Neurol Clin       Date:  2014-06-06       Impact factor: 3.806

8.  Small molecules that target the toxic RNA in myotonic dystrophy type 2.

Authors:  Lien Nguyen; JuYeon Lee; Chun-Ho Wong; Steven C Zimmerman
Journal:  ChemMedChem       Date:  2014-06-17       Impact factor: 3.466

9.  ZNF9 activation of IRES-mediated translation of the human ODC mRNA is decreased in myotonic dystrophy type 2.

Authors:  Morgan A Sammons; Amanda K Antons; Mourad Bendjennat; Bjarne Udd; Ralf Krahe; Andrew J Link
Journal:  PLoS One       Date:  2010-02-18       Impact factor: 3.240

10.  Myotonic dystrophies 1 and 2: complex diseases with complex mechanisms.

Authors:  Benedikt Schoser; Lubov Timchenko
Journal:  Curr Genomics       Date:  2010-04       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.